Innovation-Driven Pharmacovigilance (PV)

Technology advances and the impact on regulators and industry

Pharmacovigilance (PV) challenges are growing for both regulators and industry. Adverse Event (AE) case volumes and sources are growing rapidly, while personalized medicine increases complexity. Manual processes and legacy technology are creating barriers to efficiency and innovation. To successfully manage the balance of benefit vs. risk in PV, companies, and agencies will need to adopt technologies like agile PV platforms, natural language processing (NLP), and artificial intelligence (AI).

In this whitepaper, learn how the right combination of out-of-the-box Pharmacovigilance (PV) features and technology platform capabilities can help both industry and regulators “future-proof” their PV operations.

Learn more about Pega Pharmacovigilance.